458 related articles for article (PubMed ID: 31563391)
21. Correlation Between Fractional Exhaled Nitric Oxide Levels and Efficacy of Inhaled Corticosteroids in Children With Bronchial Asthma.
Gao SJ; Ge YP; Zhang CJ
Am J Ther; 2018; 25(6):e617-e625. PubMed ID: 26990963
[TBL] [Abstract][Full Text] [Related]
22. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
Özgen H; Tepetam FM; Bulut İ; Örçen C
Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
[TBL] [Abstract][Full Text] [Related]
23. Both exhaled nitric oxide and blood eosinophil count were associated with mild allergic asthma only in non-smokers.
Giovannelli J; Chérot-Kornobis N; Hulo S; Ciuchete A; Clément G; Amouyel P; Matran R; Dauchet L
Clin Exp Allergy; 2016 Apr; 46(4):543-54. PubMed ID: 26542195
[TBL] [Abstract][Full Text] [Related]
24. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
Johansson SGO; Lilja G; Hallberg J; Nopp A
Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
[TBL] [Abstract][Full Text] [Related]
25. Lung function parameters in omalizumab responder patients: An interesting tool?
Paganin F; Mangiapan G; Proust A; Prudhomme A; Attia J; Marchand-Adam S; Pellet F; Milhe F; Melloni B; Bernady A; Raspaud C; Nocent C; Berger P; Guilleminault L
Allergy; 2017 Dec; 72(12):1953-1961. PubMed ID: 28517027
[TBL] [Abstract][Full Text] [Related]
26. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
27. Different patterns of exhaled nitric oxide response to β2-agonists in asthmatic patients according to the site of bronchodilation.
Michils A; Malinovschi A; Haccuria A; Michiels S; Van Muylem A
J Allergy Clin Immunol; 2016 Mar; 137(3):806-12. PubMed ID: 26688519
[TBL] [Abstract][Full Text] [Related]
28. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
[TBL] [Abstract][Full Text] [Related]
29. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12.
Mogensen I; Alving K; Jacinto T; Fonseca J; Janson C; Malinovschi A
Clin Exp Allergy; 2018 Aug; 48(8):935-943. PubMed ID: 29575336
[TBL] [Abstract][Full Text] [Related]
30. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
31. Clinical utility of ultrahigh fractional exhaled nitric oxide in predicting bronchial hyperresponsiveness in patients with suspected asthma.
Liu J; Xu R; Zhan C; Luo W; Lai K; Zhong N; Chen W; Chen R
Postgrad Med J; 2019 Oct; 95(1128):541-546. PubMed ID: 31296792
[TBL] [Abstract][Full Text] [Related]
32. Factors reducing omalizumab response in severe asthma.
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Santus P; Perrella A; Paggiaro PL
Eur J Intern Med; 2018 Jun; 52():78-85. PubMed ID: 29395935
[TBL] [Abstract][Full Text] [Related]
33. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.
Szefler SJ; Casale TB; Haselkorn T; Yoo B; Ortiz B; Kattan M; Busse WW
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2673-2680.e3. PubMed ID: 32298853
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China.
Zhang M; Jin M; Zhou X; Lin J; Liu X; Liu C; Huang M; Wang W; Chen L; Huang Y; Li J; Zhang Q; Shen H; Yu Y; Tang W; Zhou J; Liu H; Dong L; Hu Y; Wu H; Li Y; Song W; Ouyang M; Yuan X; Wang T; Xiong S
Respir Med; 2021 Sep; 186():106522. PubMed ID: 34229289
[TBL] [Abstract][Full Text] [Related]
35. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
36. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma.
Frix AN; Schleich F; Paulus V; Guissard F; Henket M; Louis R
Biochem Pharmacol; 2020 Sep; 179():113944. PubMed ID: 32240649
[TBL] [Abstract][Full Text] [Related]
38. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
39. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
[TBL] [Abstract][Full Text] [Related]
40. [Clinical efficacy of omalizumab for treatment of moderate or severe allergic asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective study].
Luo MX; Hua S; Wei W
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Sept 15; 25(9):959-965. PubMed ID: 37718403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
